Studies in non small cell lung cancer, NSCLC, and prostate cancer cell lines have revealed that dasatinib can inhibit cell migration and invasion by preventing SRC from relaying downstream signals to proteins such as focal adhesion kinase (FAK), paxillin and p130Cas, which mediate adhesion, and MAPK and p27, implicated in cell cycle regulation [33, 34]. The gene discussed is SRC; the disease is Familial prostate cancer.